Drugs / NMRA-335140
Drug research

NMRA-335140

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as BTRX 335140; BTRX-335140; CYM-53093; Navacaprant

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs PlaceboNCT04221230NMRAPhase 2Completed2022-04-08Actual
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive DisorderNCT06058039NMRAPhase 3Completed2026-05-04Actual
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06029426NMRAPhase 3Completed2024-12-03Actual
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06058013NMRAPhase 3Completed2026-05-06Actual
Study to Assess the Safety and Effectiveness of NMRA-335140-501NCT06029439NMRAPhase 3Terminated2026-08-17Actual

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.